[go: up one dir, main page]

AR098830A2 - Suspensiones acuosas estabilizadas para administración parenteral - Google Patents

Suspensiones acuosas estabilizadas para administración parenteral

Info

Publication number
AR098830A2
AR098830A2 ARP140104760A ARP140104760A AR098830A2 AR 098830 A2 AR098830 A2 AR 098830A2 AR P140104760 A ARP140104760 A AR P140104760A AR P140104760 A ARP140104760 A AR P140104760A AR 098830 A2 AR098830 A2 AR 098830A2
Authority
AR
Argentina
Prior art keywords
parenteral administration
biologically active
methionine
active compound
compound
Prior art date
Application number
ARP140104760A
Other languages
English (en)
Original Assignee
Pfizer Italia Srl
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl, Pharmacia & Upjohn Spa filed Critical Pfizer Italia Srl
Publication of AR098830A2 publication Critical patent/AR098830A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación en suspensión acuosa farmacéutica para su administración parenteral que tiene un pH sustancialmente estabilizado, que comprende un compuesto biológicamente activo y una concentración efectiva de control del pH de L-metionina. Uso de L-metionina en la preparación de una formulación en suspensión acuosa farmacéutica que tiene un pH sustancialmente estabilizado, para la administración parenteral de un compuesto biológicamente activo, y de L-metionina y un agente de buffer en concentraciones efectivas como para producir un efecto súper-aditivo de control del pH. Reivindicación 7: Una composición farmacéutica de acuerdo con la reivindicación 6,caracterizada porque el compuesto biológicamente activo es un compuesto esteroidal. Reivindicación 8: Una composición farmacéutica de acuerdo con la reivindicación 7, caracterizada porque el compuesto esteroidal biológicamente activo se selecciona entre exemestano, medroxi-progesterona-acetato y estradiol-cipionato o una mezcla de medroxi-progesterona-acetato y estradiol-cipionato.
ARP140104760A 2000-05-15 2014-12-18 Suspensiones acuosas estabilizadas para administración parenteral AR098830A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use

Publications (1)

Publication Number Publication Date
AR098830A2 true AR098830A2 (es) 2016-06-15

Family

ID=24283530

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP010102268A AR029924A1 (es) 2000-05-15 2001-05-14 Suspensiones acuosas estabilizadas para administracion parenteral
ARP140104760A AR098830A2 (es) 2000-05-15 2014-12-18 Suspensiones acuosas estabilizadas para administración parenteral
ARP180101264A AR111695A2 (es) 2000-05-15 2018-05-14 Suspensiones acuosas estabilizadas para administración parenteral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010102268A AR029924A1 (es) 2000-05-15 2001-05-14 Suspensiones acuosas estabilizadas para administracion parenteral

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180101264A AR111695A2 (es) 2000-05-15 2018-05-14 Suspensiones acuosas estabilizadas para administración parenteral

Country Status (30)

Country Link
US (3) US6495534B2 (es)
EP (1) EP1282402B1 (es)
JP (1) JP4205341B2 (es)
KR (1) KR100828957B1 (es)
CN (1) CN100473376C (es)
AR (3) AR029924A1 (es)
AT (1) ATE313316T1 (es)
AU (2) AU2001267371B2 (es)
BR (1) BR0110841A (es)
CA (1) CA2409059C (es)
CZ (1) CZ303872B6 (es)
DE (1) DE60116084T2 (es)
DK (1) DK1282402T3 (es)
EA (1) EA007682B1 (es)
EE (1) EE05376B1 (es)
ES (1) ES2254443T3 (es)
HK (1) HK1054194B (es)
HU (1) HU229800B1 (es)
IL (2) IL152537A (es)
IN (1) IN224279B (es)
MX (1) MXPA02011195A (es)
NO (1) NO332215B1 (es)
NZ (1) NZ522324A (es)
PE (1) PE20011322A1 (es)
PL (1) PL203075B1 (es)
SI (1) SI1282402T1 (es)
SK (1) SK287641B6 (es)
TW (1) TWI256310B (es)
WO (1) WO2001087266A1 (es)
ZA (1) ZA200208738B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
CL2004000698A1 (es) * 2003-03-31 2005-05-20 Alza Corp Comosicion farmaceutica no acuosa que comprende al menos un ingrediente activo y un vehiculo de fase unica que contiene al menos un polimero y al menos un solvente, siendo el vehiculo miscible en agua; procedimiento para su preparacion; dispositivo d
BRPI0413200A (pt) 2003-09-03 2006-10-03 Miscon Trading S A método para tratamento de endometriose
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
EP1796635A2 (en) * 2004-09-14 2007-06-20 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
JP2009526860A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
WO2008039473A2 (en) * 2006-09-27 2008-04-03 Scidose Llc Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
EP2185112A4 (en) * 2007-08-21 2012-01-18 Harbor Biosciences Inc Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
MX347611B (es) 2011-06-19 2017-05-04 Abogen Inc Dispositivos, soluciones y metodos para recoleccion de muestras.
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3046544A4 (en) * 2013-09-17 2017-03-22 Terapio Corporation Methods of preventing or treating mucositis using rlip76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3423036B1 (en) 2016-03-02 2022-01-26 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
LT3943070T (lt) 2017-07-14 2024-02-12 Janssen Pharmaceutica Nv Ilgo veikimo bedakvilino preparatai
WO2019048906A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
BR112020004553A2 (pt) * 2017-09-07 2020-09-08 Teva Pharmaceutical Industries Ltd composições injetáveis de acetato de medroxiprogesterona e métodos de uso
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
CN111741756A (zh) 2018-01-11 2020-10-02 梅里蒂奇制药公司 稳定的皮质类固醇组合物
US11752095B2 (en) 2018-09-07 2023-09-12 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
MY207327A (en) 2018-11-20 2025-02-19 Spectrum Solutions Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
US20240237929A1 (en) * 2021-05-19 2024-07-18 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
ATE99943T1 (de) 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
WO1998014476A1 (en) 1996-10-04 1998-04-09 Amgen Inc. Pharmaceutical compositions containing an mpl ligand
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
IL135186A0 (en) * 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
DE69913116T2 (de) 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
AU6737101A (en) 2001-11-26
US20030114430A1 (en) 2003-06-19
EE05376B1 (et) 2011-02-15
EP1282402A1 (en) 2003-02-12
NO20025431D0 (no) 2002-11-13
CA2409059A1 (en) 2001-11-22
KR100828957B1 (ko) 2008-05-13
ES2254443T3 (es) 2006-06-16
IN224279B (es) 2005-02-25
DE60116084T2 (de) 2006-08-17
KR20030020280A (ko) 2003-03-08
NZ522324A (en) 2005-02-25
HUP0302021A3 (en) 2011-03-28
US6495534B2 (en) 2002-12-17
CN100473376C (zh) 2009-04-01
AU2001267371B2 (en) 2006-01-05
HU229800B1 (en) 2014-07-28
EA007682B1 (ru) 2006-12-29
JP4205341B2 (ja) 2009-01-07
IL152537A (en) 2007-06-17
US20030130245A1 (en) 2003-07-10
CA2409059C (en) 2006-04-18
PE20011322A1 (es) 2002-01-10
US20020115645A1 (en) 2002-08-22
PL365793A1 (en) 2005-01-10
BR0110841A (pt) 2003-03-11
EA200201208A1 (ru) 2003-04-24
AR029924A1 (es) 2003-07-23
EE200200631A (et) 2004-04-15
NO20025431L (no) 2003-01-13
WO2001087266A1 (en) 2001-11-22
HK1054194A1 (zh) 2003-11-21
ZA200208738B (en) 2003-10-29
MXPA02011195A (es) 2003-03-10
HK1054194B (zh) 2010-02-12
CN1429101A (zh) 2003-07-09
CZ303872B6 (cs) 2013-06-05
NO332215B1 (no) 2012-07-30
IL165888A0 (en) 2006-01-15
DK1282402T3 (da) 2006-05-08
JP2003533467A (ja) 2003-11-11
TWI256310B (en) 2006-06-11
EP1282402B1 (en) 2005-12-21
PL203075B1 (pl) 2009-08-31
SK287641B6 (sk) 2011-05-06
AR111695A2 (es) 2019-08-07
SK15982002A3 (sk) 2003-05-02
ATE313316T1 (de) 2006-01-15
IL152537A0 (en) 2003-05-29
HUP0302021A2 (hu) 2003-09-29
SI1282402T1 (sl) 2006-04-30

Similar Documents

Publication Publication Date Title
AR098830A2 (es) Suspensiones acuosas estabilizadas para administración parenteral
CO5700797A2 (es) Composicion de farmaco conjugado
AR052545A1 (es) Suspension no acuosa inyectable
NZ596367A (en) Lyophilized therapeutic peptibody formulations
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
NZ593190A (en) Factor viii formulations
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
CL2009000573A1 (es) Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.
AR067011A1 (es) Formulaciones de anticuerpos
AR078161A1 (es) Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
PE20070437A1 (es) FORMULACION ACUOSA hFSH
BR9916076A (pt) Composição adequada para aplicação tópica, uso de uma composição tópica métodos para melhorar o distúrbio do estìmulo sexual feminino, e para intensificar o estìmulo sexual feminino, e a resposta sexual feminina, artigo de manufatura
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
PE63998A1 (es) Composiciones anti-fungosas
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos
AR049063A1 (es) Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
ES2720954T3 (es) Formulaciones estabilizadas de estatina
UA92146C2 (ru) Стабилизированная жидкая композиция, которая содержит интерферон
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
PE20011320A1 (es) Suspension esteroidal estabilizada

Legal Events

Date Code Title Description
FB Suspension of granting procedure